Zoetis delivered flat revenue in Q2, missing Wall Street expectations, while its adjusted earnings per share slightly exceeded consensus. The market’s positi...
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are...
Zoetis (NYSE:ZTS) reported second-quarter revenue of $2.5 billion, flat on a reported basis and down 1% organically, as pressure in U.S. companion-animal categories offset growth in livestock, diagnostics and international markets. Adjusted net income was $781 million, down 2% organically, while adj
Animal health company Zoetis (NYSE:ZTS) fell short of the market’s revenue expectations in Q2 CY2026, with sales flat year on year at $2.47 billion. The comp...
Animal health company Zoetis (NYSE:ZTS) fell short of the market’s revenue expectations in Q2 CY2026, with sales flat year on year at $2.47 billion. The comp...
Animal health company Zoetis (NYSE:ZTS) will be reporting earnings this Thursday before market open. Here’s what you need to know. Zoetis missed analysts’ re...
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the...
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Zoetis (NYSE:ZTS) and its pee...
Zoetis has gotten torched over the last six months - since December 2025, its stock price has dropped 36.6% to $78.46 per share. This was partly driven by it...
The S&P 500 (^GSPC) is packed with companies that have built dominant market positions, making it a core index for investors. A select few continue to innova...
